Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma

BACKGROUND: Pancreatic carcinoma possesses one of the highest lethality rates, highest drug-resistance, and highest incidence rates. The objective of this research was to enhance the efficacy and drug-resistance for pancreatic carcinoma by using inhibition of SIRT1 combined with gemcitabine therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Dao-Jun, Zhang, Jia-Min, Yu, Min, Zhuang, Bo, Guo, Qing-Qu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718766/
https://www.ncbi.nlm.nih.gov/pubmed/23898224
http://dx.doi.org/10.2147/CIA.S45064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718766/
https://www.ncbi.nlm.nih.gov/pubmed/23898224
http://dx.doi.org/10.2147/CIA.S45064

Ejemplares similares